St. Jude Medical Advances Integration of Electrophysiology Lab Equipment with Launch of Several New Technologies

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced several new products that provide physicians and hospitals with the opportunity for improved efficiency and information connectivity in the electrophysiology (EP) lab. The EnSite Connect™ Remote Support feature, EnSite Courier™ Module, EnSite Velocity v2.0™ Software and recently launched EnSite Derexi™ Module are advanced technologies that allow a streamlined workflow within the EP lab.

Millions of people worldwide are affected by abnormal heart rhythms, creating an ongoing need for diagnostic mapping and ablative technologies. The new product offerings from St. Jude Medical allow for a simplified diagnostic and treatment process, added safety and the potential for reduced treatment time for the patient.

“Improving procedural workflow is an important way to help improve efficiency and manage the cost of delivering care,” said Jane J. Song, president of the St. Jude Medical Atrial Fibrillation Division. “Our streamlined EP Lab offerings provide advanced technologies that optimize interconnectedness and continue to move St. Jude Medical toward our ultimate goal of providing hospitals with fully integrated and networked EP labs.”

About the EnSite Products

EnSite Velocity v.2.0 Software – EnSite Velocity v.2.0 Software adds new features and enhanced performance to the EnSite Velocity System, which launched in 2009. The EnSite Velocity v.2.0 is designed to help physicians more efficiently diagnose and guide therapy to treat abnormal heart rhythms.
EnSite Connect Remote Support – EnSite Connect remote support improves lab efficiency by providing live, real-time viewing of the EnSite Velocity System screen by knowledgeable support staff. Through the use of a secure Internet connection, EnSite Connect support allows for rapid troubleshooting, system diagnosis and resolution of technical issues, eliminating the need for electrophysiologists to download and save case logs for off-site analysis.
EnSite Courier Module – The EnSite Courier Module seamlessly imports cardiac information and provides efficient networking of cardiac images such as MR, CT and 3-D rotational angiography. This networking software provides more control for the EP lab to efficiently obtain cardiac datasets when and where electrophysiologists need them.
EnSite Derexi Module – The recently launched EnSite Derexi™ Module contributes to the overall connectivity of the EP lab by providing improved efficiency and workflow, enabling communication between the EnSite™ Velocity™ Cardiac Mapping System and the EP-Workmate™ Recording System.

“The complete suite of St. Jude Medical EnSite Velocity System products allow me to more easily collect and combine very detailed anatomical and mapping data when diagnosing or treating arrhythmias,” said Dr. William Nesbitt, of Texas Health Arlington Memorial Hospital. “Compared to other systems, the user interface is very intuitive and the ease of use with such a connected system creates a more flexible, efficient environment for the entire EP team.”

About St. Jude Medical

St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. St. Jude Medical is headquartered in St. Paul, Minn. and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit sjm.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended October 2, 2010. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.

SJM (NYSE:STJ)
Historical Stock Chart
From Jul 2024 to Aug 2024